Region:Middle East
Author(s):Shubham
Product Code:KRAD0953
Pages:86
Published On:November 2025

By Type:The market is segmented into Medical Marijuana, Recreational Marijuana, Hemp Products, CBD Oil, and Cannabis-Derived Pharmaceuticals.Medical Marijuanais the leading segment, driven by its growing acceptance in mainstream healthcare and robust clinical evidence supporting its efficacy for chronic pain, epilepsy, and other conditions. Demand forCBD Oilis rising among wellness consumers seeking natural alternatives for stress, sleep, and pain management.Hemp ProductsandCannabis-Derived Pharmaceuticalsare gaining traction due to innovation in product formulations and expanding therapeutic indications.

By End-User:The end-user segmentation includes Hospitals & Clinics, Retail Pharmacies, Pharmaceutical Manufacturers, Research & Academic Institutions, and Wellness & Alternative Therapy Centers.Hospitals & Clinicsare the dominant end-user segment, increasingly incorporating medical cannabis into treatment plans for chronic conditions such as pain and epilepsy.Retail Pharmaciesplay a significant role in providing accessible options for consumers seeking over-the-counter cannabis products.Pharmaceutical ManufacturersandResearch & Academic Institutionsare actively involved in clinical trials and product innovation, whileWellness & Alternative Therapy Centerscater to the growing demand for holistic health solutions.

The Saudi Arabia Legal Marijuana Market is characterized by a dynamic mix of regional and international players. Leading participants such as Tilray Brands, Inc., Canopy Growth Corporation, Aurora Cannabis Inc., Cronos Group Inc., HEXO Corp., Sandoz (Novartis AG), GW Pharmaceuticals (Jazz Pharmaceuticals plc), Al-Dawaa Pharmacies, Nahdi Medical Company, Hikma Pharmaceuticals PLC, STADA Arzneimittel AG, Organigram Holdings Inc., Cresco Labs Inc., Columbia Care Inc., TerrAscend Corp. contribute to innovation, geographic expansion, and service delivery in this space.
The future of the legal marijuana market in Saudi Arabia appears promising, driven by increasing acceptance of medical use and potential economic benefits. As regulatory frameworks evolve, the market is likely to see enhanced investment opportunities and the development of innovative cannabis-based products. Additionally, collaboration with international firms could facilitate knowledge transfer and technological advancements, further propelling the industry forward. Overall, the market is poised for gradual growth as societal attitudes shift and regulatory barriers are addressed.
| Segment | Sub-Segments |
|---|---|
| By Type | Medical Marijuana Recreational Marijuana Hemp Products CBD Oil Cannabis-Derived Pharmaceuticals |
| By End-User | Hospitals & Clinics Retail Pharmacies Pharmaceutical Manufacturers Research & Academic Institutions Wellness & Alternative Therapy Centers |
| By Distribution Channel | Online Pharmacies Hospital Pharmacies Specialty Dispensaries Direct-to-Patient (DTP) Others |
| By Product Form | Dried Flower Edibles Oils and Tinctures Capsules & Tablets Topicals & Transdermal Patches |
| By Consumer Demographics | Age Group (18-24, 25-34, 35-44, 45+) Gender Income Level Chronic Illness Prevalence Lifestyle Preferences |
| By Geographic Distribution | Riyadh Region Jeddah/Makkah Region Eastern Province Other Regions |
| By Regulatory Compliance Level | Fully Compliant Products Partially Compliant Products Non-Compliant Products Others |
| Scope Item/Segment | Sample Size | Target Respondent Profiles |
|---|---|---|
| Legal Experts on Cannabis Regulation | 45 | Lawyers, Policy Advisors, Regulatory Consultants |
| Healthcare Professionals' Perspectives | 60 | Doctors, Pharmacists, Medical Researchers |
| Consumer Acceptance and Awareness | 120 | Potential Consumers, Patients, General Public |
| Industry Stakeholders Insights | 50 | Producers, Distributors, Retailers |
| Market Analysts and Economists | 40 | Market Researchers, Economic Advisors, Financial Analysts |
The Saudi Arabia Legal Marijuana Market is valued at approximately USD 500 million, driven by expanding legalization frameworks, increasing medical applications, and shifting consumer perceptions towards cannabis-derived therapies.